Northrop Grumman Corporation
NOC - NYSE - $555.49 ▼ -%2.03
-
Earnings Thu 23 Jul

Northrop opens the
books on Thursday evening.

4 analysts' median target is $750[FMP target], stock is $555, +35.0% upside potential. After Q1 +1.3% EPS beat[FMP earnings], the stock moved -3.5%.

summary below
Quick Take - in 40 seconds
B+
BUY Council 5/6 - Moonshot 26

B+ = MoonshotScore 26[9-pillar formula] + Council 5/6[6-lens rule]. Form 4: 0 transactions[FMP Form 4].

Q4 consensus: revenue $10.8B[FMP est], EPS $6.81[FMP est]. 4 consecutive quarters of beat[FMP earnings].

$6.81 EPS Estimate Last year $7.23 - -4% YoY YoY
4 Beat Streak Expectations beaten consecutively for the last 4 quarters

Q1 EPS +1.3% beat[FMP] but the stock -3.5% D+1[FMP D+1]. John Green promised $167.0M CapEx + a sequential decline in Q4 during the Q1 earnings call[John Green capex transcript].

Watchlist

6 metrics stand out this quarter.

$200 million Risk Indicator

Capex Increase B21

capex_increase_b21

Northrop Grumman will invest an additional $200 million in 2026 to support increased production capacity on B-21, bringing 2026 capital expenditures to $1.85 billion.

"This includes an additional $200 million we expect to invest this year to support the increased production capacity on B-21. As a result, we now expect $1.85 billion in 2026 capital expenditures."

- John Green, CFO - Q1 FY26 Earnings Call - April 21, 2026
10% Investor Focus

Missile Defense Growth

missile_defense_growth

Northrop Grumman's missile defense business accounts for nearly 10% of company sales and is well positioned to capitalize on opportunities such as Golden Dome.

"Demand in this area has been exceptionally strong, and today, our missile defense business accounts for nearly 10% of company sales. Northrop Grumman Corporation is well positioned to capitalize on opportunities such as Golden Dome, as well as other program areas."

- Kathy Warden, Chair, CEO and President - Q1 FY26 Earnings Call - April 21, 2026
10% Investor Focus

Srm Market Growth

srm_market_growth

Northrop Grumman's weapons business is nearing 10% of total company sales and is positioned to grow at a pace well above the company average.

"Overall, our weapons business is nearing 10% of total company sales and is positioned to grow at a pace well above the company average."

- Kathy Warden, Chair, CEO and President - Q1 FY26 Earnings Call - April 21, 2026
5% Investor Focus

Organic Sales Growth

organic_sales_growth

Northrop Grumman reported a 5% organic sales increase in Q1, driven by modernization projects.

"First quarter organic sales were up 5%, a great start to the year and consistent with our full year expectations."

- Kathy Warden, Chair, CEO and President - Q1 FY26 Earnings Call - April 21, 2026
25% Investor Focus

B21 Production Increase

b21_production_increase

Northrop Grumman finalized an agreement with the Air Force to increase the annual production rate of the B-21 by 25%, enhancing the program's long-term economics.

"As previously announced, we finalized an agreement with the Air Force to increase the annual production rate of the B-21 by 25%. This agreement demonstrates the strong operational requirements for the platform and confidence in our team to accelerate the delivery of this generation capability for the warfighter."

- Kathy Warden, Chair, CEO and President - Q1 FY26 Earnings Call - April 21, 2026
$1.5 trillion Investor Focus

Defense Budget Increase

defense_budget_increase

The U.S. fiscal year 2027 defense budget request increased by 44% to $1.5 trillion, emphasizing modernization.

"Earlier this month, the administration submitted a $1.5 trillion defense budget request for fiscal year 2027. The budget emphasizes modernization and represents a 44% increase over current funding levels."

- Kathy Warden, Chair, CEO and President - Q1 FY26 Earnings Call - April 21, 2026

Stock Expert AI - Methodology

Do our 9 pillars, 7 perspectives, and Munger lens point in the same direction?

Council Score 5 / 6 Bullish

6 investor frameworks. 5 bullish (Ray Dalio, Jim Simons, Klarman, Buffett, Munger), 1 bearish (Ken Griffin), 0 neutral (none).

How is it calculated? ->
Ray Dalio macro - target upside +35.0%
Ken Griffin flow - 50d MA below
Jim Simons quant - RSI 19
Klarman value - target upside +35.0%
Buffett quality - ROE score 5/5
Munger valuation - target upside +35.0%
Munger's Mindset character & balance sheet lens
Undervalued

Quality business, discounted price.

How is it calculated? ->
Financial HealthModerate
Margin of SafetyStrong
Interest CoverageAdequate
ROIC vs WACCHealthy
Technical Levels - Pre-earnings positioning

What levels is the stock being tested at?

RSI(14)
19.2 RSI 19.2 oversold, 50d below
MACD
-18.20 price below 50d - resistance dominant
50d MA
$679 stock 18.2% below - short-term resistance
200d MA
$621 stock 10.5% below - long-term pressure
Volume (10d)
-83% decrease - low participation
Resistance
$750
Analyst median target - upgrade trigger if broken
Current
$555
Pre-earnings position
Support
$528
Invalidation - close below this is a technical breakdown
Pattern
Range
$528-$750 band - earnings breakout/breakdown trigger

Past Performance

Northrop's last 8 quarters: 4 consecutive beats.

BEAT
Q2 FY25
$7.11 vs $6.92 est - +0.8%
BEAT
Q3 FY25
$7.67 vs $6.44 est - -0.5%
BEAT
Q4 FY25
$7.23 vs $6.98 est - +1.5%
BEAT
Q1 FY26
$6.14 vs $6.06 est - -3.5%

Q1 (April 21, 2026): EPS $6.14 vs $6.06 est[FMP], +1.3% beat. D+1 movement: -3.5%[FMP D+1]. Decline despite beat - market reacted to guidance, not numbers.

Three scenarios: what could happen?

EPS < $6.61 (no guidance)

Q1: EPS $6.14 vs $6.06 beat[FMP], stock -3.5% D+1[FMP].

Backlog concentration

No RPO/backlog concentration disclosed in Q1 earnings call.

CapEx shock

Q1 CapEx $167.0M[FMP cashflow]. Q1 op margin 10.0%[FMP op margin] - this level in Q4 is sensitive to CapEx revision risk.

Framework - Position discipline

After the data arrives: 3 scenarios, 3 windows

Not advice - a structural framework for earnings night. Decision discipline is yours.

Scenario A - Beat
Q4 EPS > $6.81 + CapEx discipline
Threshold: EPS > $6.81[FMP est].
Target: Break above median target $750[FMP target]; high target $815[FMP] upper bound.
Scenario B - In-Line
EPS approx $6.81 + CapEx < $167.0M
Threshold: EPS approx $6.81[FMP est], Q4 CapEx < $167.0M[FMP].
Target: Consolidation in the band between current $555[FMP] and median $750[FMP].
Scenario C - Miss
EPS < $6.61 or CapEx >= $167.0M
Threshold: EPS < $6.61[FMP estx0.97].
Target: Current $555 below SMA200 $621[FMP], if rejection continues, $528[derived] support activates.
Sizing
Earnings volatility -> max portfolio 1-2%. Waiting for earnings is not a gamble, it's a position entrustment.
Timing
IV crush within 24 hours post-earnings. Waiting for premium decay makes options preferable to spot.
Staging
Don't go all-in at once, divide into 3: initial reaction, 24 hours later, after Friday's close.

Market Outlook

What do 4 analysts say?

Wall Street Consensus
$750
12-month median target price (+35.0% upside potential)
12
BUY
12
HOLD
0
SELL
Risk Management
$528
Invalidation level - critical support threshold
$679 - 50-day MA (below, -18.2%)
$621 - 200-day MA (below, -10.5%)
IV Crush risk (sudden drop in inflated option premiums before earnings): Option premiums are inflated before earnings.
Verdict - NOC Q4 FY26
B+

You read it in 5 minutes. When the numbers come out on Thursday evening - you know what you're looking at.

Data arrives at night. The framework is ready now.

Data arrives on Thursday evening. The framework is ready on this page: Q4 EPS threshold $6.81[FMP], CapEx threshold "below $167.0M"[John Green]. Two anchors, three scenarios.

Comparison Stock Expert AI Pro $24/month ($240/year), 77% cheaper than the total of three earnings-tracking tools ($1,059/year -> $240/year).

3 subscriptions. 1 platform.

Seeking Alpha $299/yr - analyst opinions + earnings coverage TipRanks $360/yr - Smart Score (1-10) + analyst consensus + insider trades Trendspider $400/yr - AI pattern detection + automated TA + multi-timeframe alerts

Prices as of April 2026. Sources: seekingalpha.com/subscriptions - tipranks.com/pricing - trendspider.com/pricing

Stock Expert AI Pro: $24/month ($240/year). Council 7-lens analysis + MoonshotScore 9-pillar + Insider tracker + Technical levels - all in one platform, for every stock.

Educational tool, not investment advice. Past performance does not guarantee future results.

Calendar

Catalyst Calendar - 90-day forward look

Jul 23, 2026EARNINGSQ4 FY26 results (after market close) + earnings call
Jul 24, 2026PRICEFirst trading day after earnings - 200dMA test + IV crush
Sep 6, 2026FILING10-Q deadline - segment breakdown + RPO detail (SEC rule: quarter-end + 45 days)
~Oct 23, 2026EARNINGSQ1 FY27 (next quarter, date not yet scheduled in FMP)

DATA GAP: Events not in the FMP /stable/calendar feed - Investor day, analyst day, product launches, regulatory dates. These require company IR page scraping or manual calendar entry.

Frequently Asked Questions

What does the NOC earnings preview cover?

This NOC (NOC) earnings preview covers the analyst consensus, key catalysts, and what to watch on the earnings call.

What should investors watch for in NOC earnings?

Consensus EPS, revenue guidance, segment growth rates, and the tone of management commentary — the full breakdown with sources is on this page.